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Abstract: Cordyceps is a rare naturally occurring entomopathogenic fungus usually found at high altitudes
on the Himalayan plateau and a well-known medicinal mushroom in traditional Chinese medicine.
Cordyceps contains various bioactive components, out of which, cordycepin is considered most vital,
due to its utmost therapeutic as well as nutraceutical potential. Moreover, the structure similarity of
cordycepin with adenosine makes it an important bioactive component, with difference of only hydroxyl
group, lacking in the 3′ position of its ribose moiety. Cordycepin is known for various nutraceutical
and therapeutic potential, such as anti-diabetic, anti-hyperlipidemia, anti-fungal, anti-inflammatory,
immunomodulatory, antioxidant, anti-aging, anticancer, antiviral, hepato-protective, hypo-sexuality,
cardiovascular diseases, antimalarial, anti-osteoporotic, anti-arthritic, cosmeceutical etc. which makes it
a most valuable medicinal mushroom for helping in maintaining good health. In this review, effort has
been made to bring altogether the possible wide range of cordycepin’s nutraceutical potential along
with its pharmacological actions and possible mechanism. Additionally, it also summarizes the details
of cordycepin based nutraceuticals predominantly available in the market with expected global value.
Moreover, this review will attract the attention of food scientists, nutritionists, pharmaceutical and
food industries to improve the use of bioactive molecule cordycepin for nutraceutical purposes with
commercialization to aid and promote healthy lifestyle, wellness and wellbeing.
Keywords: Cordyceps; cordycepin; medicinal mushroom; nutraceutical; anti-diabetic; immunomodulator;
anti-hyperlipidemia; Chinese medicine; DongChongXiaCao; bioactive compound
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1. Introduction
Cordyceps, derived from two Latin words “cord” and “ceps” representing ‘club’ and ‘head’
respectively, describing it as club fungi. It is an entomopathogenic fungus where extensions of the
stroma and fruiting body arise from insect larvae carcasses [1]. Cordyceps predominantly lives on the
head of larvae of a particular moth species, Hepialus armoricanus Oberthur (Lepidoptera). It belongs
to the Ascomycetes family and has been a very well-known fungus in Chinese traditional medicine
for the last 300 years. Cordyceps is also known as ‘Dong Chong Xia Cao’, which means ‘Worm in
winter and grass in summer’ in China [2–4]. According to the previous reports, around 1200 types
of entomopathogenic fungi are known, out of which, Cordyceps is considered as one of the largest
genus containing approximately 500 species. Several species of Cordyceps have been cultivated for their
therapeutic properties such as Cordyceps sinensis, Cordyceps sobolifera, Cordyceps cicadicola, Cordyceps
liangshanesis, Cordyceps ophioglossoides and Cordyceps militaris [5]. On the other hand, keeping in
mind the therapeutic value, its major distribution location at approximately 14,000 ft altitude in the
Himalayan regions of China, Nepal, Tibet and India makes it very expensive at around USD ($)
12,000 kg−1 [3,6,7]. Moreover, despite the harvesting difficulties and distribution, it is still considered a
highly valued mushroom because of its abundant natural bioactive component resources with various
potent biological activities and nutraceutical importance [2]. For hundreds of years, Cordyceps were
used as a folk tonic food, but only in recent times, its potential pharmaceutical as well as nutraceutical
application have been explored, which has attracted food scientists globally [8].
Currently, it has been observed that a majority of the population from developed as well as
developing countries are suffering from chronic diseases, and the underlying causes are believed to
be rapid urbanization and changes in eating and lifestyle behavior. Among the various underline
causes, eating habits are considered one of the major risk factors for chronic diseases, such as
obesity, diabetes, hypertension, hyperlipidemia and many more affecting both wellness and the
wellbeing of mankind [9,10]. Therefore, the scientific community is working relentlessly to develop
naturally occurring or naturally derived product, such as nutraceuticals, which could help in
improving the human health status while not possessing harmful effects. Cordyceps are among
the thousands of mushroom available containing various bioactive components with innumerable
health benefits [11]. It has been used for its therapeutic values since long time and new promising
features of cordycepin-based nutraceuticals are an advantage for the current population. There is a
very well-known quote from Hippocrates stating that, “Let food be thy medicine and medicine be
thy food”, describing the importance of nutrition for the prevention, treatment and management of
diseases. Therefore, Cordyceps, as an edible mushroom, could be an ideal nutraceutical containing
both nutritionally bioactive components as well as a source of various physiological benefits [12,13].
Moreover, based on our literature search, we found that researchers have majorly discussed cordycepin
for its anticancer potential, but other therapeutic applications and potential nutraceutical approaches
have either not been discussed in detail or ignored. The main objective of this review is to focus on the
nutraceutical potential of cordycepin (the major bioactive component of Cordyceps), using a mechanistic
approach to study its pharmacological functions as well as to demonstrate the benefit of commercial
availability of cordycepin-based nutraceuticals.
2. Nutritional Value of Cordyceps
Nutrition is considered as a fundamental pillar of human beings for maintaining health or in
development across the entire life span. Moreover, it is very important to have a proper diet and enough
nutrition for survival, physical growth, mental development, performance and productivity, health
and well-being [14]. One often quoted phrase, “medicines and foods have a common origin” and based
upon this idea, Cordyceps could be considered as one of the most significant mushrooms, enriched with
various nutrients with possible nutraceutical value [12]. Abundant amounts of bioactive components
are present in Cordyceps such as proteins, fats, essential amino acids, volatile oils, carotenoids, phenolic
compounds, flavonoids, minerals (Fe, Ca, Mg, Ni, Sr, Na, Ti, Pi, Se, Mn, Zn, Al, Si, K, Cr, Ga, V and
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Zr), vitamins (B1, B2, B12, E and K) as well as various types carbohydrates like monosaccharides,
oligosaccharides, polysaccharides, sterols, nucleosides, etc. [15–19]. Proximate analysis of some of the
Cordyceps species have reported that moisture, total ash, crude protein, fat, crude fibre and carbohydrate
content are 7.18%, 7.48%, 21.46%, 1.80%, 6.40% and 55.68%, respectively [20]. Many authors have also
reported proximate analyses of Cordyceps fruiting bodies and mycelial biomass. The protein, moisture,
ash, fat, and carbohydrate compositions of Cordyceps fruiting bodies were reported as 59.8%, 5.7%,
5.1%, 8.8% and 29.1%, whereas, mycelial biomass contains 39.5%, 13.1%, 5.7%, 2.2% and 39.6% of
protein, moisture, ash, fat and carbohydrates, respectively [21]. On the other hand, the amino acid
contents of the corpus as well as fruiting bodies of Cordyceps militaris (C. militaris) were reported to be
14.03 mg/g and 69.32, respectively. Additional amino acid analysis indicates that the fruiting bodies
contains abundant amounts of proline, lysine, threonine and glutamic acid. Moreover, fatty acid
profiling indicates almost 70% of unsaturated fatty acids out of the total fat percentage. Importantly,
the amount of cordycepin and adenosine in both corpus and fruit bodies was reported to be (0.97 and
0.36%) and (0.18 and 0.06%), respectively [17,22]. With the increasing interest in Cordyceps in recent
times for pharmaceutical, nutraceutical or food biotechnological purposes, further research is necessary
to obtain an overview of the potential of this medicinal mushroom [2].
3. Bioactive Components of Cordyceps
The significance of bioactive components present in foods has been gaining interest recently
due to public health concerns. Moreover, with rising consumer awareness regarding promotion,
prevention as well as maintenance of health, bioactive components present in food could play a
very important role [23,24]. Bioactive compounds can be described as molecules present in food
derived of plant or animal sources consumed to have a regular energy intake along with various
therapeutic activities such as against metabolic disorders, anti-inflammatory, chronic diseases and
many more [25]. The presence of these bioactive components, even in minute quantities, not only
meets the basic nutritional needs, but also confers numerous health benefits. Epidemiological studies
indicate that high consumption of foods rich in bioactive compounds with different phytochemicals
such as antioxidants, vitamins, flavonoids and carotenoids has a positive effect on human health [26].
Mushrooms have been known and used for centuries for food and medicinal use. Among various
mushrooms, very well-known medicinal mushrooms like Cordyceps producing bioactive metabolites
are used or studied for the possible treatment of several diseases [15]. The presence of antioxidants
acquired by modifying our diet with mushrooms could play an important role in the prevention of
diseases. Cordyceps have a history of medicinal use spanning millennia in parts of Asia, but they can also
be potentially used for their nutraceutical values [22,27]. Cordyceps have been reported to contain various
bioactive components such as proteins, fat, carbohydrates, exopolysaccharides, cordycepin, phenolic
compounds, polysaccharides, cordycepic acid, adenosine, proteoglucans, terpenoids, amphinol, steroids,
ergosterol, lectins, etc. A detailed list of bioactive components present in Cordyceps is presented in Table 1
along with the chemical structures of some potent identified bioactive molecules (Figures 1 and 2).
Out of these, cordycepin is the main active constituent which is most widely studied for its medicinal
value along with its nutraceutical potential [2,8,22,28,29]. Moreover, various mechanisms have been
reported for the pharmacological actions of cordycepin such as inhibition of DNA and RNA synthesis,
post-transcriptional processing of hnRNA and activation of adenylate cyclase, inhibition of chemotaxis
and particular protein synthesis of macrophage cell lines, anti-tumorigenic activity on some cell lines,
enhancement of cell differentiation etc. [1].
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Table 1. List of bioactive components present in Cordyceps with their biological activities and implication
in therapeutics.
Bioactive Component Biological Activity/Therapeutic Effect References
Nucleosides
Cordycepin
Antitumor, anti-diabetic, anti-inflammatory,
antimicrobial, inhibit platelet aggregation,
hypolipidemic, analgesic, immunomodulatory
[15,30–32]
Adenosine Anticonvulsant, Anti-inflammatory, Anti-tumor [15,29,33]
Polysaccharides
Exopolysaccharide Fraction (EPSF) Anti-tumor, antioxidant, anti-inflammatory,Immunomodulatory [15,33,34]
Acid polysaccharides (APS) Antioxidant, Immunomodulatory effect [33]
CPS-1 Antioxidant [15,33]
CPS-2 Cell proliferation inhibition [33]
Mannoglucan Cytotoxicity activity [34]
CME-1 Antioxidant [33]
PS-A Inhibitory activity against cholesterol esterase [34,35]
Cordyglucan Anti-tumor [33]
D-mannitol or Cordycepic acid Diuretic, anti-tussive and anti-free radical activities [2,29,31]
Sterols
Ergosterol Antimicrobial, antiviral, anti-arrhythmic effects,Helps in bone development [2,30,31,36]
β-Sitosterol Protect from breast, colon and prostate cancer [34,36]
H1-A Immunoregulation [33]
Proteins, Amino acids and Polypeptides
CSDNase DNA hydrolysis, nucleolytic properties [33]
CSP Fibrinolytic activity [33,34]
Cordymin Anti-diabetic effect, antifungal [22,33,37]
Cordycedipeptide A Cytotoxic activity [33,38]
Cordyceamides A and B Cytotoxic activity [34,38]
Tryptophan Serves as precursor for the synthesis of theneurotransmitter’s serotonin and tryptamine [33,39]
Others
Xanthophylls Anticancer [30,31]
Fibrnolytic enzyme Treatment of thrombosis [30,31]
Proteoglucans Enhanced anticancer effect on bladder cancer cells [28,40]
Phenolic compounds
Antioxidant, antimicrobial, anti-arthritic,
anti-carcinogenic, anti-hypertensive,
cardio-protective, anti-inflammatory and anti-allergic
[28,41]
N-acetylgalactosamine Necessary for intercellular communication [22,42]
Exopolysaccharides Nutraceutical, pharmaceutical [22,43]
Chitinase, macrolides, cicadapeptins,
myriocin, superoxide dismutase, protease,
napthaquinone, cordyheptapeptide and
dipicolinic acid
- [22]
Vitamins
B1 Essential in neurologic activities [22,44]
B2 Helps in energy production [22,44]
B12 Help in cellular metabolism, DNA synthesis,methylation and mitochondrial metabolism [16,45,46]
E Antioxidant, Help in formation of blood cells,muscles, lung and nerve tissues, Increase immunity [16,44,45]
K Essential for blood clotting [22,44]
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(A) Cordycepin (B) Adenosine (C) Cordycepic acid (D) Ergosterol (E) Structure of (a) and (b).
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Figure 2. Chemical structures of some known and potent bioactive compounds in Cordyceps. (A) Stearic
acid (B) N-acetyl muramic acid (C) Hypoxanthine (D) Nephthaquinone (E) Dipliconic acid (F) Myriocin
(G) Cordyheptapeptide A (H) Cicadapepti 1.
4. Cordycepin and Its Chemical Features
Cordycepin (C10H13N5O3, molecular weight 251.24 Da, melting point 228–231 ◦C) is chemically
(9-(3-deoxy-β-D-ribofuranosyl) adenin ), 3’–deoxyadenosine [5,47]. The structure of cordycepin
consists of a purine molecule attached to one ribose sugar moiety [48]. The NMR spectrum of
Molecules 2020, 25, 2735 6 of 21
cordycepin shows a singlet at 3.4 ppm, attributed to the C-H proton and a -NH2 peak reported to be
present at 4.6 ppm, whereas, the peaks due to the different -OH groups are found to in the 8–8.5 ppm
range [47]. The concentration of cordycepin in C. militaris, i.e., around 2–3 mg/kg, is very low compared
to the needs of the commercial market, therefore various synthetic and semi-synthetic methods have
been reported for the preparation of cordycepin [49]. Cordycepin can be synthesized chemically by
replacing an OH group with an H group at the 3′-position of the ribofuranosyl moiety to produce
an adenosine analogue [50]. Cordycepin is found to be structurally very similar to adenosine except
for the lack of a 3′-hydroxyl group [49,51] Due to its very close structural similarity with adenosine,
it is considered to be a very potent bioactive component with essential properties for its nutraceutical
applications. There are various reports suggesting that cordycepin competitively inhibits the courses
of synthesis and metabolism of DNA and RNA, as well as it affects the activity of adenosine deaminase
and the mTOR signaling pathway [52]. Therefore, cordycepin has been reported to have a wide variety
of pharmacological actions such as antioxidant, immunological, hypolipidemic, anti-inflammatory,
anticancer, antimicrobial, antiviral, and hypoglycemic properties [49].
5. Cordycepin as a Nutraceutical and Its Role in Human Health
The concept of “nutraceutical” was first introduced in the survey study conducted in France,
United Kingdom and Germany, where they found that rating of diet by the consumers was much higher
compared to the other factors such as exercise or hereditary to achieve a good health [53]. DeFelice
was the first to introduce the word “nutraceutical” by coalescing the two words “nutrition” and
“pharmaceutical” and define it as “food or a part of food which not only impart health benefits but also
contributes in preventing or treating various diseases”. Moreover, in broad terms nutraceuticals can be
summarized as bioactive components which play a vital role in human beings by maintaining their
normal physiological functions and well-being [10,54]. Notably, nutraceuticals have been designed
in such a way, that it could be useful for the betterment and maintenance of human health without
causing any harm due to their natural occurrence [55,56]. Nutraceuticals of plant, animal origin or live
microorganisms offer great opportunities for food scientists and food industries to produce novel foods
or food components for the future needs of human beings to stay healthy [57,58]. Nutraceuticals have
been classified in various ways based upon their understanding and applications. Naturally available
food sources are considered for their nutraceutical values. They can be characterized as antioxidants,
dietary fibre, prebiotics, polyunsaturated fatty acids, probiotics, vitamins, polyphenols and spices [9,53].
The sudden rise in demand of nutraceutical products is mainly due to their therapeutic properties
in various ailments such as the common cold, hypertension, heart disease, arthritis, dyslipidemia,
diabetes, cancer, depression, inflammatory bowel disease, and increased life span by postponing
aging, integrity of the body and support of smooth normal functioning. Therefore, nutraceuticals
could play an important role in the improvement of health as well in chronic disease prevention [58].
Nutritionally potent Cordyceps are considered a powerhouse of energy, because of their ability to
revitalize several organ systems. Moreover, according to various scientific reports, the Cordyceps
active component cordycepin is considered very useful due to its potential application in various
ailments (Figure 3). Several pharmaceutical as well as nutraceutical preparations made from Cordyceps
dry powder (Table 2) are marketed and reported to protect renal and hepatic functions, improve
intracellular energy exchange, increases oxygenation and natural endurance, remove toxins from the
body, control blood glucose level and lipid profile, delays the aging process, stimulates the natural
metabolism of energy and nourishes the body’s immune system [59].
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Figure 3. Pictorial representation of Cordyceps therapeutic potential in general.
Table 2. Nutraceutical products from Cordyceps available on the global market.
Product Name Health Benefit Claim Manufacturer
Mycoformulas Endurance™ Enhancement of intracellular energy exchange,increases oxygenation and natural endurance Myco Formulas, USA
Nutricafe-organic Increases physical endurance and helps to removetoxins from your body Aloha Medicinals USA
Mushroom Plus Supporting immune system, energy levelsand cognition Link Nutrition Ltd., UK
Dragon Herbs Increases the primary stimulating force forlife activities Iherb Holdings LLC, USA
OM™ Maitake Supports weight control and blood sugar balancing Yukiguni Maitake CO., LTD, Japan
Host Defense Mushrooms Energy support Host Defense, USA
CaféCeps® Packets Numbers of health-enhancing properties, Madre Labs LLC, France
Bhutan Cordyceps Tea
Immunity booster, Anticancer, Anti-aging,
Antioxidant, Improve kidney and
gastrointestinal systems
Bhutan Natural, Singapore
MRM Cordyceps CS-4 Strain
It strengthens the immune system, respiratory
system and cardiovascular system, Strengthens the
natural metabolism of energy
All Star Health, USA
Ultra Cordyceps Plus
Help boost physical energy and stamina, improve
vitality, support lung health, liver function, memory
and mental ability
Doctor’s Best, USA
Now Foods Cordyceps Immune health support Now Foods, USA
Exploding Buds Cordyceps Sinensis Immune health support Iherb Holdings LLC, USA
Fungiology from California Gold
Nutrition
For healthy immunity and health promotion of the
entire body California Gold Nutrition, USA
Planetary Herbals Cordyceps
POWER CS-4 Energy support Michael Tierra, USA
Cordyceps Capsules, Extracts
or Powders Energy support and stamina Host Defense Mushrooms, USA
Cordyceps active Promotes mental health, Ensure perfect oxygenationof the heart and vascular system Terezia, Czech
Collagen C ReLift Capsules For less wrinkles and improved complexion Zein Pharma, Germany
MycoNutri Cordyceps Organic Immune system support The Really Healthy, UK
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6. Mechanism of Action and Pharmacological Implications of Cordycepin
6.1. Cordycepin and Diabetes
Diabetes has recently become one of the most prevalent epidemics worldwide, affecting almost 382
million people. According to the reports, it is believed that every year approximately 1.3 million people
die from diabetes. According to International Diabetes Federation (IDF), it is estimated that around
629 million people will be diabetic around the globe by 2045. However, as per the recommendation
from dieticians or physicians, a healthy life style and healthy food habits, could be one of the key
answers to this problem [60,61]. It has also been observed that, in most diabetic patients, several other
complications also arise, such as cardiovascular diseases, retinopathy, nephropathy, hyperlipidemia and
neuropathy [62]. Of note, it is also suggested by various studies, that no single treatment programme
can treat diabetes, although most of the treatments achieve normal blood glucose levels or improve
microcirculation [63]. Currently, pharmaceutical products used for the management or therapeutic
purposes against diabetes are sulfonylureas, biguanides, thiazolidinedione, α-glucosidase inhibitors
or insulin injections. However, pharmaceutical products available for the treatment of diabetes have
several adverse effects and their potency is sometimes controversial. Other non-medicinal strategies
used in diabetes are exercise, weight loss plans and changes in food habits. Occasionally, complications
of diabetes can cause morbidity because of pathophysiology flaws. Therefore, consumer interest
has currently moved towards alternative medicinal approaches such as nutraceutical food products
containing bioactive antidiabetic components. Some studies have reported that extract of C. militaris
showed a significant decrease in blood glucose levels by virtue of increasing glucose metabolism as
well as protection against diabetic nephropathy [64].
The mechanism of cordycepin’s antidiabetic activity is not fully understood, but a few studies
have explained a possible pathway. They found that cordycepin prevents the production of NO and
pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6 in LPS activated macrophages by inhibiting
the protein expression of pro-inflammatory mediators. By virtue of this the expression of type 2
diabetes-regulating genes (11β-HSD1 and PPARλ) was reduced. Expression of co-stimulatory molecules
such as ICAM-1 and B7-1/-2 was also decreased with the increase in cordycepin concentration as
presented in Figure 4A [65]. Furthermore, cordycepin has been found to suppress the expression of
diabetes-regulating genes through the inactivation of NF-κb-dependent inflammatory responses [66,67].
In another study, cordycepin’s antidiabetic activity was reported in an alloxan-induced diabetic mouse
model. The results suggested a significant improvement in glucose tolerance tests after administration
of an effective dose of cordycepin [68]. Additionally, an effect of cordycepin on diabetic nephropathy
by suppressing cell apoptosis, renal fibrosis and rescued cell autophagy in the diabetic nephropathy
rat model was also reported [69]. There are several reports which suggest that cordycepin has very
good potential for being a safe anti-diabetic pharmaceutical agent [64,65,70].
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Figure 4. (A) Possible mechanism of cordycepin for its anti-diabetic activity (B) Possible mechanism of
cordycepin in regulation of fat metabolism in hyperlipidemia [47].
6.2. Cordycepin and Cardiovascular Diseases (Hyperlipidemia)
Cardiovascular diseases have become one of the major causes of death around the world in
developed as well as developing countries, and it has been assumed that there are various factors
(excessive intake of tobacco, alcoholism, sedentary lifestyle, unhealthy eating habits etc.) associated
with it. Among the various risk factors, rises in lipid levels are believed to be one of the main ones
causing this chronic disease [71]. Hyperlipidemia is caused by or considered as the amount of fatty acids
present in lipids, low density lipoprotein cholesterol, trans fats and triglycerides accumulated in human
bodies causing cardiovascular diseases such as atherosclerosis and coronary heart disease [72–74].
Moreover, a mechanistic approach involved in the regulation of fat metabolism is due to AMP-activated
protein kinase (AMPK), a main cell electricity sensor [75]. In addition, activation of AMPK causes a
decline in levels of fatty acids through phosphorylation and inhibition of acetyl-CoA carboxylase (ACC),
which helps in regulation of fatty acid biosynthesis and oxidation (Figure 4B). AMPK activation was also
reported to decrease total cholesterol and triglycerides by inhibiting the activity of glycerol-3-phosphate
acyltransferase (GPAT) and HMG CoA reductase, the two rate-limiting enzymes in TC and TG synthesis,
respectively [76]. Wu et al. [77] proposed that cordycepin could additionally prevent intracellular
lipid accumulation through activation of AMPK interplay with the
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hyperlipidemia [78]. According to previous reports, cordycepin has been found very effective in lipid
reduction, due to its chemical structural similarity with adenosine (an activator of AMPK). Similarly,
administration of cordycepin was able to reduce the accumulation of low-density lipoprotein cholesterol,
total cholesterol and triglycerides effectively, and could be a potent nutraceutical agent for reducing
hyperlipidemia caused by high fat diets [79,80]. On the other hand, cordycepin was also evaluated for
regulating autophagy as well as lipid metabolism. It has been found that cordycepin was effective
against hepatic lipid accumulation induced by PA through autophagy induction and PKA/mTOR
pathway could be the possible mechanism behind its efficacy. More importantly, it was observed that
cordycepin was largely effective in reducing the intracellular levels of total lipids, total cholesterol,
C and TG, LDL-C, VLDL-C as well as LDL-C/HDL-C and TC/HDL-C ratios. Therefore, cordycepin
lipid-lowering activity could be of potential use in the treatment of hyperlipidemia [77,79,81].
6.3. Cordycepin and Anti-Inflammatory Effects
Inflammation, a natural response to injury, occurs in our body to eliminate harmful elements such
as damaged cells, irritants and pathogens by initiating the healing system. Acute and chronic pulmonary
inflammations have been reported in various respiratory diseases such as asthma, acute respiratory
distress syndrome, cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) [82]. Of note,
cordycepin has been reported to suppress intestinal irritation in an acute colitis mouse model as well
as in microglia through inhibiting pro-inflammatory mediators such as TNFα [83,84]. It has been
found that cordycepin is effective in a mouse version of bronchial asthma as well as it improves
both mucus clearance and airway surface hydration, as it is hyper-secreted in various respiratory
problems, like COPD and asthma [85,86]. In addition, cordycepin has also been reported to attenuate
airway remodeling in rats with COPD by preventing airway inflammation as well as TGF-β1/Smad
signaling pathway. According to this report, cordycepin could be useful in the case of COPD [87,88].
Cordycepin extracts were reported to relieve fibrosis in the lung by inhibiting TGF-b1 expression [89,90]
and the promotion of collagen degradation [91]. Therefore, based upon these collective reports and
data, it could be summarized that cordycepin has all the potential to become a very potent bioactive
anti-inflammatory component [83–85,92].
6.4. Cordycepin and Immunomodulatory Effects
Immunomodulation is usually defined as modulation of the immune system, and this can be
done by any chemical agent that modifies the immune response or the functioning of the immune
system via the stimulation of antibody formation or the inhibition of white blood cell activity [93].
Cordycepin has been reported to stimulate cytokine release of resting peripheral blood mononuclear
cells (PBMCs) as well as influence PBMCs proliferation and transcription factors in a human acute
monocytic leukemia cell line (THP-1). Moreover, cordycepin was found to regulate human immune
cells functions in vitro [94,95]. It has also been observed that the antitumor activity of cordycepin is
associated with its immunomodulatory effects [96]. Additionally, pure bioactive components extracted
from C. militaris are reported to have good immunomodulatory effects by increasing the survival rate of
lupus mice and reducing anti-ds-DNA production [34,65]. Zhang and Xia [97] observed that C. sinensis
behaves like an immunosuppressant in a heterotopic heart allograft model in rats and increases the
survival period. The same effect has been reported by other authors too, for example, Zhu and Hu [98],
revealed that C. sinensis prolongs the mouse skin allograft survival time. Therefore, cordycepin has
been proven a potentially effective immunomodulator, and it is even specifically used to control
autoimmune disorders and transplant rejections after an organ transplant [99]. An increasing number
of studies indicate that cordycepin is a bi-directional modulator with both suppressive as well as
influencing effects on the immune system by regulating the adaptive and innate immunity [1,100–103].
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6.5. Cordycepin and Anti-Osteoporosis Effect
Osteoporosis is a condition of low bone mineral density (BMD) and loss of the structural and
bio-mechanical properties of bones. It increases the risk of fracture, as bones become more porous and
fragile. Osteoporosis mainly occurs in aged people, specifically in post-menopausal women and patients
who had long-term treatment of steroid therapy. Anti-osteoporotic effect of cordycepin was studied in
ovariectomized osteopenic rats, it has been found that cordycepin was able to counteract the loss of
bone in the experimental model. The mechanistic approach used in this study showed the decline in
activity of tartrate-resistant acid phosphatase and alkaline phosphatase enzymes both in vitro and in vivo.
Moreover, the results showed that oral intake of cordycepin could increase the level of osteocalcin (OC),
a marker of bone formation, and decrease C-terminal cross-linked telopeptide of type I collagen (CTX)
level, a marker of bone resorption, as well as restore oxidative stress levels in ovariectomized rats [104].
These results suggest that cordycepin can be a valuable bioactive compound for the treatment of
osteoporosis and is able to prevent bone loss caused by estrogen deficiency. Cordycepin was also
reported to inhibit RANKL-induced osteoclast differentiation (RANKL), receptor activator of nuclear
factor kappa-B ligand, and down-regulate the mRNA expressions of osteoclastogenesis-related genes
such as, matrix metalloproteinase (MMP)-9, cathepsin K, tartrate-resistant alkaline phosphatase (TRAP)
and nuclear factor of activated T-cells, cytoplasmic 1 [105].
6.6. Cordycepin and Anti-Arthritic Effect
Arthritis, an autoimmune disease affecting bone joints, is mainly characterized by joint stiffness
as well as joint pain, among other symptoms such as swelling, warmth, redness, and reduction in
joint motility. There is no known specific effective treatment for arthritis, although many drugs
such as glucocorticosteroids, non-steroidal anti-inflammatory drugs, and other biological agents are
used to improve the symptoms, such as pain, fatigue, and disability. Long-term usage of these
drugs decreases their effectiveness and increases side effects. Recently, studies were conducted
looking for effective anti-arthritic drugs with increased therapeutic effects and fewer side effects.
Traditional herbal medicine, which is shown to be more effective, safer, and economical, has attracted
more attention in the area of arthritis treatment. Moreover, cordycepin has been found to modulate
glycosaminoglycan (GAG) release by suppressing stimulation of IL-1β. In addition, levels of proteases
that have been reported in cartilage matrix degradation, such as MMP-13, cathepsin K, MMP-1,
cathepsin S, ADAMTS-5 and ADAMTS-4, were decreased by cordycepin in a dose-dependent manner.
Chondroprotective effect of cordycepin by preventing cartilage denegation as well as interfering
inflammatory response in osteoarthritis pathogenesis has also been reported [106]. Cordycepin has
been reported to reduce excessive inflammatory cell infiltration via down-regulation of macrophages,
interferon gamma-induced protein 10 (IP-10) and Mig expressions through terminating protein coding
gene (STAT1) phosphorylation [107]. There are some reports suggesting that inflammation of T-cell
infiltration could be inhibited by using a cordycepin concentration of 10 mg/kg. According to that
report, cordycepin can regulate the T-cell receptor, a protein complex found on the surface of T-cells,
that signals to suppress excessive T-cell activation in inflammation [108]. Therefore, based upon
these reports, it can be concluded that cordycepin has therapeutic potential in both anti-catabolic and
anti-inflammatory actions against arthritic diseases [107,108].
6.7. Cordycepin and Antioxidant Effect
Antioxidants are compounds that can prevent or slow down oxidation reactions producing
free radicals, that ultimately cause cell damage in organisms. Oxidative stress, which is related
with an increased formation of oxidizing species or a significant reduction of natural antioxidant
levels, is involved in different human diseases (cellular necrosis, cardiovascular disease, cancer,
neurological disorder, ageing) [109]. Non-toxic antioxidants from natural sources, particularly
medicinal plants, are known to prevent oxidative damage due to their richness in polyphenolics and
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bioactive compounds [110–114]. The antioxidant activity of Cordyceps has been reported by various
authors [115,116]. Cordycepin has been reported to significantly increase the levels of antioxidant
enzymes such as superoxide dismutase and glutathione peroxidase activities in 6-OHDA-treated cells.
Moreover, the results showed that cordycepin prevents 6-OHDA-induced neurotoxicity in adrenal
pheochromocytoma cells (PC12 cells) via its potent antioxidant action [117]. In addition, cordycepin
containing protein-bound polysaccharide causes a reduction in lipid peroxidation as well as an increase
in the activity of antioxidant enzymes in the liver like catalase and superoxide dismutase [118].
Other authors have suggested the potential of cordycepin in reducing lipid peroxidation in mouse
liver [119]. Therefore, per these reports, cordycepin could be considered as a potential antioxidant.
A few studies have even suggested that the antioxidant potential of Cordyceps is close to that of ascorbic
acid [120].
6.8. Cordycepin and Anti-Malarial Effect
Malaria, a very common disease globally with a high mortality rate, is caused by Plasmodium,
a parasitic organism [121–124]. The parasite gets into the human body through the bites of infected
mosquitoes [125–127]. It is one of the deadliest diseases in the world [128], as it is estimated that
every 2 min, a child dies of malaria, and each year more than two hundred million new cases of the
disease are reported [129]. Most of the people who die from the disease are young children in Africa.
The effects of cordycepin on the malaria parasite in mice were first studied by Trigo et al. [130]; they
suggested that the growth of the parasite was affected by cordycepin that affects the nucleic acid and
protein synthesis of the parasite. This makes cordycepin a possible molecule which can be explored
further as a probable anti-malarial agent.
6.9. Cordycepin and Other Diseases
Hyperuricemia is a long-time purine metabolic disorder recognized as a result of excessive serum
uric acid status in blood and associated with gout, renal sicknesses, hypertension, hyperlipidemia,
and atherosclerosis [96,131]. C. militaris has been reported for its anti-hyperuricemic effect in hyperuricemic
mice at different doses, reaching the levels of normal mice [132]. In another study, Yong et al. [133]
also reported cordycepin’s potential as an anti-hyperuricemic in hyperuricemic mice. Infertility can
be described as a disease condition where females are not able to become pregnant despite having
frequent, unprotected sex for at least a year for most couples. According to the reports, cordycepin has
been proved potent in increasing both the sperm quality and quantity. C. militaris supplementation
has been stated to bring about an increase of serum cordycepin concentration, which concurrently
enhances testosterone and estradiol-17 levels, ultimately increasing the percentage of motile sperm
cells [134]. In addition to this cordycepin is also reported to increase semen production as well as
sperm quality in boars [66]. The effect of cordycepin on testosterone levels in male rats was reported.
It was found that the concentration of testosterone in the serum of the rats was significantly increased
by C. militaris. Therefore, fruiting bodies of C. militaris grown on the drone bee medium could
act as an integrative medicine for the treatment of reproductive problems caused by insufficient
testosterone levels in human males [135]. On the other hand, chronic kidney disease (CKD) is a disease
condition where the condition of the kidneys deteriorates steadily and has been related with both
non-communicable diseases, e.g., diabetes and hypertension, and infectious diseases like hepatitis B,
malaria, and HIV [136]. Clinical research exploring the possible cordycepin application has confirmed
the beneficial effects in decreasing the progression of end-stage kidney disease in CKD patients [137].
Moreover, other pharmaceutical applications of cordycepin are also recommended, such as increasing
creatinine clearance, serum albumin and hemoglobin, lowering serum creatinine levels as well as
improving lipid metabolism [137–140].
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7. Global Nutraceutical Market of Cordycepin: Current and Future Trend
Nutraceuticals are developed from foods or food derived components due to their health promoting
properties to establish a clear link between ‘nutrients’ and ‘pharmaceuticals’ [9]. The health promoting
effects of nutraceuticals have led to substantial increases in their market predominantly since the 1990s.
Nutraceutical products have shown hope for various chronic diseases (diabetes, cancer, heart disease,
hypertension, common cold, dyslipidemia, arthritis and many more) as well as help in delaying aging
and eventually increasing life span [58]. Health awareness in consumers, caloric intake and weight
management in countries like US, China and India, have already endorsed various applications of
nutraceuticals, causing a significant impact on the industry growth. According to the data published
online by the Grand View research team, the global nutraceutical market size could reach USD
722.49 billion by 2027, and is expected to expand at a CAGR of 8.3% over the forecast period [141].
Major key companies such as Abbott, Amway, Danone S.A., Nestle S.A., Glanbia Nutritionals, Herbalife
International of America, Inc., The Archer Daniels Midland Company, BASF SE, PepsiCo, Inc., General
Mills, Inc. are involved in the research & development of nutraceutical production [142]. On the other
hand, the global cordycepin market is predicted to surpass US$ 1 billion by 2026. Asia Pacific (mainly
China) is considered as the global leader in the production or extraction of cordycepin from C. sinensis
and C. militaris, with an expected 47% of global nutraceutical market (Figure 5) [143].
Figure 5. Expected global nutraceutical market by 2025 with China, India, Tibet and Nepal as global
leaders for production and extraction of cordycepin [144].
8. Safety and Efficacy
Cordyceps, a well-known traditional Chinese medicine is also called a miracle mushroom because
of its exceptional health benefits. Due to its natural occurrence, it is considered pharmacologically safe
for human consumption. However, in some cases it has been reported to cause dry mouth, nausea,
abdominal distension, throat discomfort, headache and diarrhea as well as allergic reactions [22,34,145].
It is recommended to avoid its consumption in the case of patients suffering from systemic lupus
erythematosus, multiple sclerosis and rheumatoid arthritis. Moreover, there are a few reports indicating
that Cordyceps intake can cause lead poisoning in some cases. Considering the potential for toxicity,
resistance and its efficiency, potential drug derivatives designed from the natural products for the
adenosine deaminase-resistant properties and low-toxicity causing effects of cordycepin, as well
as organ-targeted nanoparticles for cordycepin delivery for in vivo therapy, are also needed [146].
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Further clinical, experimental as well as epidemiological data are required for identification of other
molecular targets to see the correlation between Cordyceps and other diseases like cancers and to
estimate the validation of optimum dosing for its safety and efficacy [28]. The mechanism of action
of cordycepin still needs further detailed scientific studies along with exploration of the various
biochemical pathways involved. Thereby, its pharmacological and mechanism of actions will help in
scientific scrutiny to answer every aspect of cordycepin [34]. Aside from some negative reports and
clinical data, Cordyceps is still relatively considered safe and non-toxic for human consumption [22].
9. Conclusions and Future Perspectives
Over the past few years, people have shown confidence and trust in naturally occurring food-based
products such as nutraceuticals for the treatment or management of various chronic diseases. Medicinal
mushrooms have been proved to be very effective against numerous serious ailments. Cordyceps,
some of the most important medicinal mushrooms, have been in use in the traditional Chinese
medicine system since a long time ago. They are considered an excellent reservoir of various bioactive
components, of which cordycepin is believed to have the most nutraceutical potential. Based on several
research reports, cordycepin indicates its nutraceutical values by showing possible therapeutic activity
against various diseases by modulating a number of cellular signaling pathways due to its redox
behavior. In future, it would be important to uncover other unknown molecules present in Cordyceps
and to understand their therapeutic potential. Likewise, it is equally important for the scientific
community to explore the possibilities of nano-biotechnology-mediated targeted drug delivery systems
for cordycepin and how to enhance its bioavailability. Further experimental and clinical studies are
required to identify the exact mechanism behind the role of cordycepin, as well as its efficacy and
safety alone and in combination. Since Cordyceps are edible, they will play a key role in the prevention
and cure of various ailments caused by metabolic disorders or infections.
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